| St Name | Version | Level | Disease | Condition | First | Last | Center | Target N | Regist N | % | Progress | |||
| CISL2302 ZRICE | V 5.5 | Phase 1/2 | DLBCL | 2nd-line | 2024-02-15 | 2024-08-26 | 1 | 72 | 12 | 16.7% | https://bbecrf.com/zrice/ | 40 | ZRICE | |
| CISL2303 VR2 | V 5.5 | Phase 1/2 | DLBCL | Salvage | 2024-05-29 | 2024-08-29 | 1 | 52 | 5 | 9.6% | https://bbecrf.com/vr2/ | 39 | VR2 | |
| CISL2301 SIENA | V 5.5 | Phase 1/2 | B-NHL | 2nd-line | 2024-06-12 | 2024-07-24 | 1 | 44 | 3 | 6.8% | https://bbecrf.com/siena/ | 38 | SIENA | |
| CISL2206 TARANIS | V 5.5 | Phase 2 | NKTCL | 1st-line | 2023-05-18 | 2024-09-09 | 6 | 38 | 16 | 42.1% | https://bbecrf.com/taranis/ | 37 | TARANIS | |
| CISL2204 BRM | V 5.5 | Phase 2R | MCL | 1st-line | 2022-10-17 | 2024-08-20 | 5 | 90 | 6 | 6.7% | https://bbecrf.com/brm/ | 17 | BRM | |
| CISL2203 GPL | V 4.3 | Phase 2 | DLBCL | Salvage | 2022-05-30 | 2024-07-17 | 19 | 102 | 89 | 87.3% | https://bbecrf.com/gpl/ | 16 | GPL | |
| CISL2202 ACANTHUS | V 4.3 | Phase 1/2 | TFHL | 1st-line | 2024-09-10 | 8 | 41 | 19 | 46.3% | https://bbecrf.com/acanthus/ | 15 | ACANTHUS | ||
| CISL2104 LARCH | V 4.2 | Phase 2 | DLBCL | 1st-line | 2021-02-22 | 2024-09-12 | 11 | 100 | 95 | 95.0% | https://bbecrf.com/larch/ | 14 | LARCH | |
| CISL2102 ICING | V 4.2 | Phase 2 | NKTCL | Salvage | 2023-05-09 | 7 | 37 | 38 | 102.7% | https://bbecrf.com/icing/ | 13 | ICING | ||
| CISL2004 ICON | V 3.8 | Cohort | CLL | Registry | 2020-05-29 | 2024-07-09 | 6 | 30 | 30 | 100.0% | https://bbecrf.com/icon/ | 12 | ICON | |
| CISL2002 OBICOM | V 3.8 | Cohort | CLL | Registry | 2019-12-05 | 2023-05-18 | 8 | 31 | 33 | 106.5% | https://bbecrf.com/obicom/ | 11 | OBICOM | |
| CISL1911 HOLY | V 3.0 | Retrosp | HL | Registry | 2023-01-25 | 17 | 500 | 181 | 36.2% | https://bbecrf.com/holy/ | 10 | HOLY | ||
| CISL1910 MCLRR | V 3.0 | Retrosp | MCL | Salvage | 2019-08-21 | 2019-12-05 | 17 | 100 | 88 | 88.0% | https://bbecrf.com/mclrr/ | 9 | MCLRR | |
| CISL1908 COGETB | V 3.0 | Cohort | DLBCL | Registry | 2019-09-24 | 2021-04-01 | 8 | 200 | 41 | 20.5% | https://bbecrf.com/cogetb/ | 8 | COGETB | |
| CISL1904 MCLR | V 3.5e | Cohort | MCL | Registry | 2024-09-11 | 43 | 1050 | 849 | 80.9% | https://bbecrf.com/mclr/ | 7 | MCLR | ||
| CISL1903 R2A | V 3.0 | Phase 2 | B-NHL | Salvage | 2021-01-26 | 13 | 66 | 64 | 97.0% | https://bbecrf.com/r2a/ | 6 | R2A | ||
| CISL1902 HOT | V 3.0 | Cohort | HL | Registry | 2019-12-19 | 2024-09-09 | 15 | 300 | 129 | 43.0% | https://bbecrf.com/hot/ | 5 | HOT | |
| CISL1802 FIXATION | V 1.5 | Phase 2 | MCL | Maintenance | 2019-03-19 | 2021-12-10 | 9 | 30 | 30 | 100.0% | https://bbecrf.com/fixation/ | 4 | FIXATION | |
| CISL1801 LEMONT | V 4.0 | Phase 2 | PTCL | Maintenance | 2019-02-14 | 2023-06-12 | 11 | 79 | 58 | 73.4% | https://bbecrf.com/lemont/ | 3 | LEMONT | |
| CISL1705 CREMA | V 1.3 | Phase 2 | NHL | 1st-line | 2018-11-30 | 2020-11-17 | 13 | 35 | 35 | 100.0% | https://bbecrf.com/crema/ | 2 | CREMA |
Are you sure delete this study?